N@N

AMI Research: AMI Research Publishes Q2 2009 Stock Report on NeoGenomics

^{Published on 2009-08-11 07:24:49, Last Modified on 2009-08-11 07:24:57 - Market Wire}
 

KEY LARGO, FL--(Marketwire - August 11, 2009) - AMI Research, a division of Hawk Associates, today announced that it has updated its stock opinion of NeoGenomics, Inc. (OTCBB: [ NGNM ]) based on the company's second quarter results. The 20-page stock research report on NeoGenomics is comprehensive and informative. It's a look into the company's core business model, financial history and future prospects.

AMI's report details the impact of NeoGenomics' strategic supply agreement with the healthcare giant Abbott Health. The report projects a favorable outcome regarding the company's initiative to develop a FISH-based skin cancer test and AMI also reports that NeoGenomics has recently restructured one of its alliances to enlarge its product portfolio and widen its geographical footprint.

To read AMI Research's report on NeoGenomics' recent news, key statistics, healthcare industry trends and more the stock report is available to download for free at: [ http://www.amistockreports.com ].

NeoGenomics specializes in cancer genetics, flow cytometry and molecular diagnostic testing. The company's laboratories offer superior service, industry leading turnaround times and complete dedication to its clients and patients. Headquartered in Fort Myers, FL, NeoGenomics has laboratories in Nashville, TN, Irvine, CA and Fort Myers and provides diagnostic tests to pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, please visit [ http://www.neogenomics.org ].

About AMI Research

AMI Research is a leading provider of issuer-paid stock research coverage and a division of Hawk Associates Inc. AMI Research offers high quality and credible fundamental analysis of promising small companies that do not have traditional Wall Street analyst coverage. Please visit [ http://www.amistockreports.com ].

AMI Research abides by the Best Practice Guidelines Governing Analyst and Corporate Issuer Relationships, developed by the CFA Institute in conjunction with the National Investor Relations Institute (NIRI). The cost of a one-year continuing research program is $30,000 prepaid for four research reports. AMI does not accept payment of fees in company shares. All AMI Research and Hawk Associates personnel are prohibited from trading in securities of covered companies. Neither the analyst's compensation nor the compensation received by AMI Research is in any way related to the specific ratings or views contained in this research report.